Myriad Genetics insider filing: CFO departure and share disposition reported

Rhea-AI Filing Summary

Scott J. Leffler, listed as Chief Financial Officer and reporting person for Myriad Genetics Inc. (MYGN), filed an "Exit" Form 4 stating he is no longer serving as CFO effective August 15, 2025. The Form 4, filed August 18, 2025, reports a disposition of 218,393 shares of Common Stock (transaction code D) and indicates the filer is no longer subject to Section 16 reporting. The filing was submitted on behalf of Mr. Leffler by Justin Hunter. No derivative transactions or additional compensation details are included in this Form 4.

Positive

• Voluntary and timely disclosure notifying the market that the reporting person is no longer subject to Section 16 reporting
• Form 4 explicitly reports a transaction (disposition of 218,393 shares), providing transparency on insider activity

Negative

• Chief Financial Officer departure effective August 15, 2025 is a material leadership change with no accompanying explanation in this filing
• Large disposition of 218,393 shares was reported without price or context (e.g., 10b5-1 plan), leaving investor uncertainty

Insights

Financial Analyst

TL;DR: CFO departure and a sale of 218,393 shares were disclosed; this is a material governance event but the filing lacks context on successor or reasons.

The disclosure shows an insider exit and a large disposal of common stock, which can affect investor perception and short-term stock dynamics. The Form 4 does not state proceeds, price, or whether the sale was part of a pre-established plan. Absent further context on replacement CFO, timing, or strategic rationale, the event is best viewed as a governance change with potential near-term informational impact but unclear long-term financial implications.

Corporate Governance Expert

TL;DR: Voluntary "Exit" Form 4 signals the reporting person left the CFO role on August 15, 2025; filing is procedurally appropriate but factually sparse.

The filing correctly notifies the market that the reporting person is no longer subject to Section 16. It lacks explanatory detail such as resignation reason, transition arrangements, or whether the disposition reflects tax planning or other personal reasons. For governance assessment, follow-up disclosures from the company about interim/permanent CFO appointment are necessary to judge succession quality and controls continuity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leffler Scott J.

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								218,393	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This "Exit" Form 4 is voluntarily filed to report solely that the Reporting Person is no longer serving in the role of Chief Financial Officer of the Company, effective August 15, 2025, and therefore is no longer subject to Section 16 reporting.

	By: Justin Hunter For: Scott J. Leffler	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for MYGN filed August 18, 2025 disclose?

The filing states that Scott J. Leffler is no longer serving as CFO effective August 15, 2025 and reports a disposition of 218,393 shares of common stock.

Does this Form 4 explain why the MYGN CFO left?

No. The Form 4 only states the reporting person is no longer serving as CFO; it does not provide reasons or details about a successor.

Was the sale part of a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the transaction was made pursuant to a 10b5-1 plan or provide any execution/deemed execution dates.

Who signed the Form 4 on behalf of the reporting person?

The filing was submitted By: Justin Hunter For: Scott J. Leffler with a signature date of 08/18/2025.

Are there any derivative transactions reported for MYGN in this filing?

No. The Form 4 contains no entries in Table II for derivative securities; only a common stock disposition is reported.